Drug
Futibatinib clinical trials
Also written TAS-120 and Lytgobi.
- studies test it
- 20
- open now
- 10
- in phase 3
- 6
- first study started
- 2014
Keep track of what changes. Save the futibatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2021 (5); 3 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 5 |
| 2023 | 1 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 13
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 11
Taiho Oncology, Inc. (8) · Northwestern University (2) · UNICANCER (2) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Mayo Clinic (1) · Yuanquan Yang (1) · American Society of Clinical Oncology (1) · Taiho Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Olaparib (3) · Pembrolizumab (3) · Fulvestrant (2) · Capmatinib (2) · Durvalumab (2) · Ivosidenib (2) · Zanidatamab (2) · Trastuzumab (2)
Studies
Open first, then newest update. How each study uses futibatinib is read from its arms, and is right about nine times in ten.
Testing it · 20
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingPhase 1Northwestern UniversityNCT07594548Written as Futibatinib
- Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyRecruitingPhase 2Yuanquan YangNCT06263153Written as Futibatinib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Futibatinib
- Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementRecruitingPhase 2Taiho Oncology, Inc.NCT05727176Written as TAS-120
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingPhase 3UNICANCERNCT07745296Written as Futibatinib
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingPhase 3Taiho Pharmaceutical Co., Ltd.NCT07710885Written as Futibatinib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Futibatinib
- Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC TrialNot yet recruitingPhase 2Northwestern UniversityNCT07639528Written as Futibatinib
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Futibatinib
- A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)RecruitingPhase 2Vall d'Hebron Institute of OncologyNCT03767075Written as Futibatinib
- Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Active, not recruitingPhase 2/3Taiho Oncology, Inc.NCT06506955Written as futibatinib
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014Written as TAS-120
- A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial CarcinomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT05036681Written as Futibatinib
- Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial CarcinomaTerminatedPhase 2Taiho Oncology, Inc.NCT04601857Written as Futibatinib
- Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver CancerCompletedPhase 2Mayo ClinicNCT04828486Written as Futibatinib
- A Study of TAS-120 in Patients With Metastatic Breast CancerTerminatedPhase 2Taiho Oncology, Inc.NCT04024436Written as Futibatinib
- Futibatinib in Patients With Specific FGFR AberrationsTerminatedPhase 2Taiho Oncology, Inc.NCT04189445Written as Futibatinib
- A Study of TAS-120 in Patients With Advanced Solid TumorsCompletedPhase 1/2Taiho Oncology, Inc.NCT02052778Written as Futibatinib
- Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene RearrangementsTerminatedPhase 3Taiho Oncology, Inc.NCT04093362Written as Futibatinib
- Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant CancerTerminatedPhase 1Taiho Oncology, Inc.NCT04965818Written as Futibatinib and Binimetinib
Given in every arm · 3 — futibatinib is usual care beside what is tested
- AB122 Platform StudyRecruitingPhase 1Taiho Pharmaceutical Co., Ltd.NCT04999761Written as TAS-120
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsActive, not recruitingPhase 2Taiho Oncology, Inc.NCT05945823Written as Futibatinib
- Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsTerminatedPhase 1Boundless Bio, Inc.NCT05827614Written as Futibatinib
Codes
What other systems call futibatinib · ClinicalTrials.gg INT001542
- MeSH (NLM) C000713257futibatinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4B93MGE4ALFUTIBATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q76791462futibatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114283FutibatinibOne source FDA
- DrugBank DB15149One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000713257 | futibatinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4B93MGE4AL | FUTIBATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76791462 | futibatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114283 | Futibatinib | One source FDA |
| DrugBank | DB15149 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.